Background: This meta-analysis evaluated the clinicopathologic and prognostic significance of RASSF1A promoter methylation in renal cell carcinoma (RCC).
Introduction
Renal cell carcinoma (RCC) is the most common malignant tumor affecting the kidneys, accounting for about 90% of kidney carcinomas. 1 Approximately 63,990 new RCC cases were diagnosed in the USA in 2017, and these were associated with an estimated 14,400 deaths. 2 There are two common histological subtypes of RCC. Clearcell RCC (ccRCC) is the most common, accounting for 70%-80% of all renal cancer cases. Papillary RCC (pRCC) represents another 10%-20% of cases. 3, 4 Approximately 25%-30% of patients with RCC present with advanced or metastatic disease, and the 5-year survival rate is poor. 5 tumor suppressor gene, RASSF1A is involved in cell cycle regulation, microtubule stabilization, cellular adhesion and motility, and cell apoptosis. [12] [13] [14] RASSF1A promoter methylation has been reported in tissue, blood, and urine samples from patients with RCC. [15] [16] [17] There are, however, inconsistent results regarding the level of RASSF1A promoter methylation in patients with RCC and controls. For example, Ellinger et al reported that the RASSF1A promoter had a similar methylation rate in RCC and adjacent normal tissue samples. 18 In contrast, RASSF1A promoter methylation was more frequent in RCC than in adjacent normal tissue samples in a study by Loginov et al. 19 With this background of conflicting results, we conducted a meta-analysis to assess differences in RASSF1A promoter methylation between RCC and control tissue, blood, and urine samples. Moreover, we evaluated the association of RASSF1A promoter methylation with clinicopathologic features and prognosis in patients with RCC.
Materials and methods search strategy
A systematic literature search of the PubMed, EMBASE, EBSCO, Wanfang, and CNKI databases was conducted to identify eligible studies published through December 1, 2017, without any language restrictions. The following keywords and scientific search terms were used: (kidney OR renal) AND (cancer OR tumor OR neoplasm OR carcinoma) AND (methylation OR methylated OR hypermethylation OR epigene*) AND (RAS association domain family protein 1A OR RASSF1A OR RASSF1 OR RAS association domain family protein 1). We manually searched the relevant references from all eligible articles to find other potential publications.
selection criteria
Articles that met the following inclusion criteria were selected for the meta-analysis: 1) patients were confirmed with adult RCC by histopathologic examination; 2) studies reported sufficient data to evaluate differences in RASSF1A promoter methylation between the RCC and control groups; 3) studies had sufficient data to assess the correlation of RASSF1A promoter methylation with clinicopathologic features; and 4) studies provided enough survival data to evaluate the prognostic effect of RASSF1A promoter methylation in RCC. When multiple papers using the same patient population were published, the study with more information was included in the meta-analysis.
Data extraction
The following information was extracted from the included publications: surname of the first author, year of publication, country, ethnic population, cancer stage, mean or median age, sample type, detection method, histologic type, number of cases and controls, survival data with multivariate analysis, and clinicopathologic features such as age ($50 vs ,50 years), gender (male vs female), tumor grade (3-4 vs 1-2), clinical stage (3-4 vs 1-2), T classification (pT2-4 vs pT1), histologic subtypes (pRCC vs ccRCC), lymph node metastasis (yes vs no), and distant metastasis (yes vs no).
The cancer genome atlas (Tcga) dataset
Clinical information for RCC, which included two sets of samples (methylation 450 K dataset: 275 pRCCs and 319 ccRCCs), was downloaded from the TCGA data portal (https://portal.gdc.cancer.gov/repository). The cutoff value of RASSF1A promoter methylation was set by its median value. The association between clinicopathologic characteristics and RASSF1A promoter methylation was analyzed using logistic regression (R; v.3. 
statistical analysis
All data analyses were performed using Stata software 12.0 (StataCorp LP, College Station, TX, USA). Differences in RASSF1A promoter methylation between RCC and control samples and the correlation of RASSF1A promoter methylation with the clinicopathologic characteristics of patients with RCC were calculated using pooled ORs and the corresponding 95% CIs. Overall HRs with their 95% CIs were also calculated to determine the prognostic role of RASSF1A promoter methylation, using multivariate analysis if possible. The Cochran's Q statistic was used to estimate possible heterogeneity among studies. 20, 21 A random-effects model was applied in the meta-analysis. When substantial heterogeneity was measured (P,0.1), a sensitivity analysis was carried out to determine the influence of an individual study on the pooled OR and heterogeneity by deleting one study at a time. 22, 23 For results covered by more than nine studies, possible publication bias was detected with Egger's test. 24 We performed trial sequential meta-analyses (TSA) to reduce type I error and to calculate the estimated required sample size information. 25, 26 For significant results with more than one study, the type I error rate was set at 
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RASSF1A promoter methylation in RCC 5% and the type II error rate was considered to be 20% (a statistical test power of 80%). The relative risk reduction was set at 20% in the meta-analysis. If the cumulative Z-curve crossed the trial sequential monitoring boundary or the required information size, the statistical evidence was deemed conclusive. Otherwise, additional studies would be needed for a definitive result. 27, 28 Results study characteristics Figure 1 summarizes the details of the study selection procedure; 22 publications with a total of 1,421 patients with RCC and 724 controls fulfilled the inclusion criteria and were selected for the meta-analysis. [15] [16] [17] [18] [19] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Of the included publications, 15 assessed differences in RASSF1A promoter methylation between RCC and control samples using tissue samples and 6 used blood or urine samples. Sixteen studies evaluated the relationships between RASSF1A promoter methylation and the clinicopathologic characteristics of patients with RCC. Two studies reported information on survival in patients with RCC using multivariate analysis. The baseline characteristics of the included publications are presented in Tables 1 and S1 . Figure 2 ). In addition, in a comparison of 76 RCCs and 115 nonmalignant urine samples, RASSF1A promoter methylation was significantly higher in RCC than in nonmalignant urine samples (OR=17.54, 95% CI=6.60-46.66, P,0.001; Figure 2 ).
correlation of RASSF1A promoter methylation with age and gender in rcc Seven studies that included 321 patients with RCC demonstrated that RASSF1A promoter methylation was not correlated with age (OR=1.00, 95% CI=0.50-2.04, P=0.99; Figure 3 ). Eight studies that included 537 patients with RCC showed that RASSF1A promoter methylation was not correlated with gender (OR=0.95, 95% CI=0.51-1.76, P=0.86; Figure 3 ).
correlation of RASSF1A promoter methylation with lymph node status and distant metastasis in rcc
In seven studies that included 438 patients with RCC, RASSF1A promoter methylation was not associated with lymph node metastasis (OR=1.72, 95% CI=0.76-3.87, Figure 4 ). Four studies that included 257 patients with RCC showed that there was no correlation between RASSF1A promoter methylation and distant metastasis (OR=1.66, 95% CI=0.75-3.69, P=0.21; Figure 4 ).
P=0.192;
correlation of RASSF1A promoter methylation with tumor grade and clinical stage in rcc
In 13 studies that included 686 patients with RCC, a significant relationship was observed between RASSF1A promoter methylation and tumor grade (OR=3.59, 95% CI=1.85-6.95, P,0.001; Figure 5 ). RASSF1A promoter methylation was also linked to clinical stage in eight studies that included 463 patients with RCC (OR=2.15, 95% CI=1.34-3.45, P=0.001; Figure 5 ).
correlation of RASSF1A promoter methylation with T classification and histologic subtypes in rcc
In seven studies that included 306 patients with RCC, a significant correlation was found between RASSF1A Figure 3 Forest plot of the association of RASSF1A promoter methylation with age (Or=1.00, 95% ci=0. promoter methylation and T classification (OR=2.66, 95% CI=1.11-6.39, P=0.029; Figure 6 ). RASSF1A promoter methylation was also significantly associated with histologic subtypes in eight studies that included 472 patients with RCC (OR=2.91, 95% CI=1.61-5.23, P,0.001; Figure 6 ).
Prognostic role of RASSF1A promoter methylation using multivariate analysis
Kawai et al reported that RASSF1A promoter methylation was a poor prognostic factor in terms of cancer-specific survival among 179 patients with ccRCC (HR=1.78, 95% CI=1.18-2.78). 31 Klacz et al reported that RASSF1A promoter methylation was not associated with overall survival using multivariate analysis among 58 patients with ccRCC. 16 More studies with large patient population are needed to further investigate the prognostic role of RASSF1A promoter methylation in RCC.
Publication bias
There was no evidence of publication bias using Egger's test for the comparison of RCC vs control tissue samples (P=0.782) or in relation to tumor grade (P=0.547; Figure 7 ).
Trial sequential meta-analysis
As shown in Figures 8 and 9 , based on the a priori anticipated information size method for significant results, when cancer was compared with control tissue samples, the cumulative Z-curve crossed the trial sequential monitoring boundary and the required information size (Figure 8) , suggesting conclusive results. When cancer was compared with control blood or urine samples, the cumulative Z-curve was more than the conventional boundary, but did not cross the trial sequential monitoring boundary (Figure 8 ), which suggests that more studies are needed to inform these two results. In relation to tumor grade, clinical stage, and histologic subtypes, the cumulative Z-curve was more than the trial sequential monitoring boundary (Figures 8 and 9 ), which suggests that additional studies are not necessary. In relation to T classification, the cumulative Z-curve crossed the conventional boundary, but did not cross the trial sequential monitoring boundary (Figure 8) , suggesting that further studies are essential. 
Tcga dataset

Discussion
Tumor suppressor genes are commonly inactivated via promoter methylation within the CpG islands, which may affect several biological processes, including cell proliferation, cell death, cell migration, and cell invasion, and contribute to the initiation and progression of human cancers. 46, 47 Studies have indicated that methylation of the promoter of the tumor suppressor gene RASSF1A reduces its expression, which may play an important role in RCC carcinogenesis. 40, 43 However, potential differences in methylation between RCC and control tissue samples have remained unclear owing to conflicting evidence from previous studies. Two studies showed that RASSF1A promoter methylation correlated negatively with RCC. 33, 38 Four studies reported no association between RASSF1A promoter methylation and RCC. 18, 32, 34, 36 Also, nine other studies showed that RASSF1A promoter methylation correlated positively with RCC. 19, 37, [39] [40] [41] [42] [43] [44] [45] The present metaanalysis including all eligible publications with large patient populations demonstrated that RASSF1A promoter methylation was notably higher in RCC than in adjacent or normal tissue samples; TSA revealed that the result was conclusive. This suggests that RASSF1A promoter methylation is significantly associated with RCC carcinogenesis.
When RCC was compared with control tissue samples, a subgroup analysis of ethnicity showed that RASSF1A promoter 
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RASSF1A promoter methylation in RCC methylation was associated with RCC in Caucasians, but not in Asians, which suggests that only the Caucasian population is susceptible to RASSF1A promoter methylation. A subgroup analysis of detection method demonstrated that RASSF1A promoter methylation correlated with RCC in the MSP subgroup, but not in the non-MSP subgroup, which indicates that the MSP method may be sensitive to the detection of RASSF1A promoter methylation. We performed a sensitivity analysis because substantial heterogeneity was measured in the comparison of cancer and control tissue samples. When four studies 32, 33, 36, 38 were successively removed and the pooled OR was recalculated, remaining significant, there was no evidence of heterogeneity (P=0.693). It is possible that the main cause of heterogeneity in this meta-analysis was contamination of adjacent normal tissue samples by cancer cells in these four studies. In addition, Egger's test showed no publication bias. The relevant analyses supported the stability and credibility of our results.
RASSF1A promoter methylation was associated with RCC in blood and urine samples (cancer vs nonmalignant controls), which suggested that RASSF1A promoter methylation may become a promising noninvasive biomarker for the detection of RCC in the future. According to the results of TSA, additional prospective clinical studies with large sample sizes are required to further investigate whether RASSF1A promoter methylation could be used as a biomarker for the diagnosis of RCC based on blood or urine samples.
Finally, we evaluated whether RASSF1A promoter methylation was linked to clinicopathologic characteristics and prognosis in patients with RCC. RASSF1A promoter methylation did not correlate with age, gender, lymph node status, or distant metastasis. Significant relationships were observed between RASSF1A promoter methylation and tumor grade, clinical stage, and T classification, with methylation notably higher in high-grade vs low-grade tumors, advanced vs early-stage patients, and high (pT2-4) vs low (pT1) T classification. These analyses suggest that RASSF1A promoter methylation may be closely associated with RCC progression. TSA showed that additional studies are essential to inform the analyses of T classification, but that the analyses of tumor grade, clinical stage, and tumor histology were robust. Additionally, TCGA data showed that RASSF1A promoter methylation remained significantly associated with pRCC vs ccRCC (OR=23.19, P,0.001), suggesting that it may play a more important role in the pathogenesis of pRCC. On multivariate analysis, RASSF1A promoter methylation was associated with poorer cancer-specific survival among 179 patients with ccRCC patients, 31 but did not correlate with overall survival among 58 patients with ccRCC patients. 16 Further analysis using TCGA data showed that no correlation was found between RASSF1A promoter methylation and overall survival on multivariate analysis (HR=0.921, P=0.687) in 567 RCCs. More studies using multivariate analysis will be crucial to confirm the prognostic impact of RASSF1A promoter methylation on cancer-specific survival.
The current results compare favorably with the previous meta-analyses by Yu et al 48 and Huang et al. 49 Yu et al only analyzed whether RASSF1A promoter methylation was correlated with RCC in cancer vs nontumor controls, 48 and RASSF1A promoter methylation did not correlate with RCC in tissue samples. 48 Our result involving a greater number of eligible studies with a larger population (15 studies with 1,296 tissue samples) showed that RASSF1A promoter methylation was significantly associated with RCC in tissue samples. In addition, Yu et al 48 49 did not analyze whether RASSF1A promoter methylation was associated with prognosis (cancer-specific survival or overall survival) or other clinical features such as gender, T stage, and lymph node status.
The current meta-analysis had several limitations. First, the size of the population with blood or urine samples was small. Second, the populations of the included studies mainly consisted of Asians and Caucasians, with limited numbers of other ethnic subgroups, such as Africans. Third, only two studies reported the prognostic role of RASSF1A promoter methylation using multivariate analysis in RCC.
Conclusion
The present findings show that RASSF1A promoter methylation correlates with RCC in tissue, blood, and urine samples. RASSF1A promoter methylation is not linked to age, gender, lymph node status, distant metastasis, or overall survival, but it is associated with tumor grade, clinical stage, T classification, histologic subtypes, and cancer-specific survival on multivariate analysis. Based on TSA, additional studies with large sample sizes are needed to validate these results Abbreviations: APIS, a priori anticipated information size; RRR, relative risk reduction.
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Zhuang et al α Figure 9 Trial sequential analysis assessing the required sample information in relation to tumor histology. Abbreviations: APIS, a priori anticipated information size; RRR, relative risk reduction.
in cancer vs control blood and urine samples and to confirm the findings regarding T classification and prognosis.
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